JWH-120

JWH-120 is a synthetic cannabinoid from the naphthoylindole family, which acts as a full agonist at both the CB1 and CB2 cannabinoid receptors, but with moderate selectivity for CB2. It was discovered by and named after John W. Huffman, an organic chemist at Clemson University.

Chemistry

JWH-120 is part of the naphthoylindole family of synthetic cannabinoids. It is structurally related to other synthetic cannabinoids such as JWH-018 and JWH-073. The compound is made by substituting an alkyl group at the nitrogen atom of the indole core, and a naphthoyl group at the carbonyl group of the indole.

Pharmacology

JWH-120 acts as a full agonist at the CB1 and CB2 cannabinoid receptors, with a moderate selectivity for CB2. The CB1 and CB2 receptors are part of the endocannabinoid system, which plays a role in a variety of physiological processes including pain sensation, mood, and memory. The effects of JWH-120 on the human body are similar to those of cannabis, but it is much more potent than traditional cannabis.

Legal Status

The legal status of JWH-120 varies by country. In the United States, JWH-120 is a Schedule I controlled substance, which means it has a high potential for abuse and no accepted medical use. In other countries, such as the United Kingdom and Germany, JWH-120 is also controlled under their respective drug laws.

Health Risks

As with other synthetic cannabinoids, the use of JWH-120 can lead to serious health risks. These include acute kidney injury, acute psychosis, and seizures. Long-term use can lead to addiction and withdrawal symptoms.

See Also

• Synthetic cannabinoids
• Cannabinoid receptor
• John W. Huffman

This article is a stub related to pharmacology. You can help WikiMD by expanding it!

This article is a stub related to pharmacology. You can help WikiMD by expanding it!